Login
Navigate Fool.com
Will LXRX beat
the market?
Community Rating: 2 Stars: Unattractive

1.63 0.08 (5.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.56
Previous Close $1.55
Daily Range $1.50 - $1.64
52-Week Range $1.39 - $3.18
Market Cap $837.5M
P/E Ratio -8.15
Dividend (Yield) $0.00 (0.0%)
Volume 1,410,431
Average Daily Volume 1,588,039
Current FY EPS -$0.16

How do you think LXRX
will perform against the market?

Top LXRX Bull/Bear Pitches

 

sandybdr (< 20)
Submitted August 16, 2011

Biopharma company that works on mouse genetics , localizes potential drug targets , and then attempts to make drugs specific for those targets. Completely speculative play. If LX4211 succeeds (phase I … More

0 Replies Reply Report this Post
 

Brosan (1.25)
Submitted January 28, 2011

With more less than 80c per share available in cash, LXRX will have a very hard time to keep their heads above water. The me-too compound, LX4211, seems to be stuck in the ground due to the lack of in … More

1 Replies Reply Report this Post

News & Commentary

Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?

This Texas-based biotech reported positive proof-of-concept results earlier this week and could be set to upend a number of big pharmaceutical companies if its experimental drug continues to deliver.

Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat Estimates

Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia

Lexicon, Alimera, and Akebia are the top stories to watch in the biotech sector this Monday morning.

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatmen

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatment

Lexicon Pharmaceuticals up 25% on drug trial

3 Stocks Near 52-Week Lows Worth Buying

Do Procera, Barclays, and Lexicon Pharmaceuticals deserve a second chance? You be the judge!

3 Biotech Companies That Could Be the Next Intercept or InterMune

With Intercept and InterMune stocks jumping 525% and 171%, respectively, biotech-savvy investors are eagerly looking for the next big thing. It just might be one of these three companies.

Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart

Lexicon Pharmaceuticals will focus its efforts on late-stage drug development, which will lead to the loss of 115 jobs.

Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)

Neurocrine Biosciences isn't up nearly as much as it appears.

3 Stocks Near 52-Week Lows Worth Buying

Do these fallen angels deserve a second chance? You be the judge!

See More LXRX News...

Sector

Healthcare

Industry

Drugs

Lexicon Pharmaceuticals, Inc. (LXRX) Description

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Website: http://www.lexicon-genetics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks